Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.

MLA

Moneer, Osman, et al. “Agreement of Treatment Effects from Observational Studies and Randomized Controlled Trials Evaluating Hydroxychloroquine, Lopinavir-Ritonavir, or Dexamethasone for Covid-19: Meta-Epidemiological Study.” BMJ: British Medical Journal, vol. 377, no. 8337, May 2022, pp. 1–14. EBSCOhost, https://doi.org/10.1136/bmj-2021-069400.

APA

Moneer, O., Daly, G., Skydel, J. J., Nyhan, K., Lurie, P., Ross, J. S., & Wallach, J. D. (2022). Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. BMJ: British Medical Journal, 377(8337), 1–14. https://doi.org/10.1136/bmj-2021-069400

Chicago

Moneer, Osman, Garrison Daly, Joshua J. Skydel, Kate Nyhan, Peter Lurie, Joseph S. Ross, and Joshua D. Wallach. 2022. “Agreement of Treatment Effects from Observational Studies and Randomized Controlled Trials Evaluating Hydroxychloroquine, Lopinavir-Ritonavir, or Dexamethasone for Covid-19: Meta-Epidemiological Study.” BMJ: British Medical Journal 377 (8337): 1–14. doi:10.1136/bmj-2021-069400.